Endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: extending endocrine sensitivity.

Antonio Frassoldati, Laura Biganzoli, Roberto Bordonaro, Saverio Cinieri, Pierfranco Conte, Michelino De Laurentis, Lucia Del Mastro, Stefania Gori, Rossella Lauria, Paolo Marchetti, Andrea Michelotti, Filippo Montemurro, Giuseppe Naso, Paolo Pronzato, Fabio Puglisi, Carlo Alberto Tondini

Research output: Contribution to journalArticlepeer-review

Abstract

Targeted agents have significantly prolonged survival and improved response rates in first- and second-line settings of hormone receptor-positive/HER2-negative metastatic breast cancer. Optimal sequencing of the available options may prolong endocrine sensitivity, slow disease progression and delay the need for chemotherapy. However, the optimal treatment sequence remains unclear and therapeutic decisions are complex. We review the latest recommendations and supporting evidence for endocrine therapy in women with hormone receptor-positive/HER2-negative metastatic breast cancer and discuss strategies for the optimal sequential therapy in scenarios of response to endocrine therapy. Although more data are needed to define the best sequence of endocrine treatments, more personalized sequential strategies, which take into account response to previous treatments as well as disease symptoms and safety issues, will be increasingly feasible.
Original languageUndefined/Unknown
Pages (from-to)129-145
Number of pages17
JournalFuture oncology (London, England)
Volume16
DOIs
Publication statusPublished - Feb 1 2020

Keywords

  • Antineoplastic Combined Chemotherapy Protocols
  • therapeutic use
  • Breast Neoplasms
  • drug therapy
  • genetics
  • pathology
  • Cyclin-Dependent Kinase 4
  • Female
  • Humans
  • Molecular Targeted Therapy
  • Neoplasm Metastasis
  • Protein Kinase Inhibitors
  • Receptor
  • ErbB-2
  • Receptors
  • Estrogen
  • Progesterone
  • CDK4/6 inhibitor
  • abemaciclib
  • endocrine therapy
  • fulvestrant
  • metastatic breast cancer
  • palbociclib
  • ribociclib

Cite this